IceCure gets 180-day Nasdaq bid-price extension
IceCure Medical reports that Nasdaq has granted the Company an additional 180-day period, until November 9, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
IceCure Medical reports that Nasdaq has granted the Company an additional 180-day period, until November 9, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its ordinary shares.
The extension follows a prior 180-day window that ended on May 11, 2026, during which IceCure did not regain compliance. The Company has indicated it intends to cure the deficiency and may, if needed, implement a reverse share split. If the closing bid price is at least $1.00 for a minimum of 10 consecutive business days before November 9, 2026, Nasdaq will deem the Company compliant, though Nasdaq can require up to 20 days.
The notice has no immediate effect on the listing or trading of IceCure’s ordinary shares, which continue to trade on the Nasdaq Capital Market under the ticker ICCM.
Insights
Nasdaq grants IceCure more time, but bid-price risk remains.
Nasdaq has given IceCure Medical a second 180-day period, until November 9, 2026, to restore its share price to at least $1.00. This follows an initial 180-day window that ended on May 11, 2026 without the Company regaining compliance.
The Company met all other Nasdaq Capital Market listing criteria, so the only deficiency involves the minimum bid price rule. IceCure has notified Nasdaq that it plans to cure the issue and may, if necessary, execute a reverse share split, which mechanically boosts the per-share price without changing overall market value.
To regain compliance, the closing bid must be at least $1.00 for 10 consecutive business days before November 9, 2026, although Nasdaq can extend this requirement up to 20 days. Until then, ICCM shares continue trading normally, but future disclosures will clarify whether price levels or any reverse split achieve sustained compliance.
Key Figures
Key Terms
minimum bid price rule regulatory
Nasdaq Capital Market market
forward-looking statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IceCure Medical (ICCM) announce regarding its Nasdaq listing?
Why is IceCure Medical (ICCM) out of compliance with Nasdaq rules?
How can IceCure Medical regain compliance with Nasdaq’s minimum bid price?
What deadlines has Nasdaq set for IceCure Medical’s bid-price compliance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: May 2026 (Report No. 5)
Commission File Number: 001-40753
ICECURE MEDICAL LTD.
(Translation of registrant’s name into English)
7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On May 13, 2026, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement”, a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.
This Report on Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit No. | ||
| 99.1 | Press release dated May 13, 2026, titled “IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement.” |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ICECURE MEDICAL LTD. | |||
| Date: May 13, 2026 | By: | /s/ Eyal Shamir | |
| Name | Eyal Shamir | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares
CAESAREA, Israel, May 13, 2026 -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until November 9, 2026 to regain compliance with Nasdaq’s minimum bid price rule.
Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split.
In a notification letter dated November 12, 2025, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company’s ordinary shares no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until May 11, 2026, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180-calendar-day compliance period and submitted a written request to the Nasdaq’s staff to afford it an additional 180-day compliance period to cure the deficiency, which it was granted in a notification letter dated May 12, 2026.
If at any time before November 9, 2026, the closing bid price of the Company’s ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company’s ordinary shares to maintain a bid price of at least $1.00 for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.
This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol “ICCM.”
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, IceCure is using forward-looking statements when it discusses regaining compliance with Nasdaq’s continued listing requirements, and the timing and effect thereof as well as potentially effecting a reverse share split. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in IceCure’s Annual Report on Form 20-F filed with the SEC on March 17, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, IceCure disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914